Zealand Pharma (Nasdaq: ZEAL) to Ring The Nasdaq Stock Market Opening Bell
August 09 2017 - 10:08AM
What: Zealand Pharma (Nasdaq:ZEAL), a
biotechnology company focused on the discovery, design and
development of innovative peptide-based medicines, will visit the
Nasdaq MarketSite in Times Square.
In honor of the occasion, Britt Meelby Jensen, President
& CEO, will ring the Opening Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Thursday, August 10, 2017 – 9:15 a.m. to
9:30 a.m. ET
Zealand Pharma Media Contact:Alette Pramming+45
53735750apr@zealandpharma.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Opening
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market open of your choice.
About Zealand PharmaZealand Pharma A/S (Nasdaq
Copenhagen:ZEAL) ("Zealand") is a biotechnology company focused on
the discovery, design and development of innovative peptide-based
medicines. Zealand has a portfolio of medicines and product
candidates under license collaborations with Sanofi and Boehringer
Ingelheim, and a pipeline of internal product candidates focusing
on specialty gastrointestinal and metabolic diseases.
Zealand's first invented medicine, lixisenatide, a once-daily
prandial GLP-1 receptor agonist for the treatment of type 2
diabetes, is licensed to Sanofi. Lixisenatide is marketed as
Adlyxin® in the U.S. and as Lyxumia® in the rest of the world.
Lixisenatide has been developed in a combination with basal insulin
glargine (Lantus®) and is marketed as Soliqua® 100/33 in the U.S.
and has been approved as Suliqua® in Europe and launched in the
Netherlands.
Zealand's clinical pipeline includes: dasiglucagon* (ZP4207,
single-dose rescue treatment) for acute, severe hypoglycemia (Phase
3); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); and
dasiglucagon* (ZP4207, multiple-dose version) intended for use in a
dual-hormone artificial pancreas system to reduce the risk of
hypoglycemia and better diabetes management (Phase 2) and other
indications, as well as other earlier-stage clinical and
preclinical peptide therapeutics.
Zealand is based in Copenhagen (Glostrup), Denmark. For further
information about the Company's business and activities, please
visit www.zealandpharma.com or follow Zealand on Twitter
@ZealandPharma.
* Dasiglucagon and glepaglutide are proposed International
Nonproprietary Names (pINN).
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
global provider of trading, clearing, exchange technology, listing,
information and public company services. Through its diverse
portfolio of solutions, Nasdaq enables customers to plan, optimize
and execute their business vision with confidence, using proven
technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 90
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to approximately 3,900 total listings
with a market value of approximately $12 trillion. To learn more,
visit: http://business.nasdaq.com
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024